Prevention

The first US COVID-19 vaccine breaks ground again, as the first authorized for patients as young as 12 years old.

New real-world research suggest the vaccine may help provide control of the pandemic virus.

A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.

New analysis of registry data suggest pregnant persons are not facing particularly worse pregnancy nor neonatal outcomes after mRNA vaccination.

Escalating usage and more drug choices are putting more people at risk.

This approach can help with clinical outcomes and mortality, but resistance is not as well defined.

Ongoing education and proven outcomes need to aid this form of testing.

An interventional cardiologist discusses the observed cases of cerebral venous thrombosis in women administered the Johnson & Johnson COVID-19 vaccine.

Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.

A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.

An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.

Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.

The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.

The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.

Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.

A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.

The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.

Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.